The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The economic burden of antibiotic resistance: A systematic review and meta-analysis
Open accessAbstract
Introduction: Antibiotic resistance (ABR) has substantial global public health concerns. This systematic review aimed to synthesise recent evidence estimating the economic burden of ABR, characterised by study perspectives, healthcare settings, study design, and income of the countries. Methods: This systematic review included peer-reviewed articles from PubMed, Medline, and Scopus databases, and grey literature on the topic of the economic burden of ABR, published between January 2016 and December 2021. The study was reported in line with ‘Preferred Reporting Items for Systematic Review and Meta-Analysis’ (PRISMA). Two reviewers independently screened papers for inclusion first by title, then abstract, and then the full text. Study quality was assessed using appropriate quality assessment tools. Narrative synthesis and meta-analyses of the included studies were conducted. Results: A total of 29 studies were included in this review. Out of these studies, 69% (20/29) were conducted in high-income economies and the remainder were conducted in upper-and-middle income economies. Most of the studies were conducted from a healthcare or hospital perspective (89.6%, 26/29) and 44.8% (13/29) studies were conducted in tertiary care settings. The available evidence indicates that the attributable cost of resistant infection ranges from -US$2,371.4 to +US$29,289.1 (adjusted for 2020 price) per patient episode; the mean excess length of stay (LoS) is 7.4 days (95% CI: 3.4–11.4), the odds ratios of mortality for resistant infection is 1.844 (95% CI: 1.187–2.865) and readmission is 1.492 (95% CI: 1.231–1.807). Conclusion: Recent publications show that the burden of ABR is substantial. There is still a lack of studies on the economic burden of ABR from low-income economies, and lower-middle-income economies, from a societal perspective, and in relation to primary care. The findings of this review may be of value to researchers, policymakers, clinicians, and those who are working in the field of ABR and health promotion. Systematic review registration: CRD42020193886
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“…that did not report mean and standard deviation (SD) but provided median and interquartile range (IQR) or range (e.g. for our outcome variables costs, length of stay (LoS)) these data were converted into mean and standard deviation using methods suggested in the published literature [37– 40].”
Luo, D., Wan, X., Liu, J., & Tong, T. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280216669183 · Cited by 4,066
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)
Downes, M. J., Brennan, M. L., Williams, H. C., & Dean, R. S. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011458 · Cited by 2,376
Antimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024
Cosgrove, S. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499406 · Cited by 1,271
Antibiotic Resistance in the Food Chain: A Developing Country-Perspective
Founou, L. L., Founou, R. C., & Essack, S. Y. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01881 · Cited by 714
Founou, R. C., Founou, L. L., & Essack, S. Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189621 · Cited by 710
The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Eliopoulos, G. M., Cosgrove, S. E., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/375081 · Cited by 637
Optimally estimating the sample standard deviation from the five‐number summary
Shi, J., Luo, D., Weng, H., Zeng, X., Lin, L., Chu, H., & Tong, T. (2020) · Research Synthesis Methods · doi:10.1002/jrsm.1429 · Cited by 611
Estimating the burden of antimicrobial resistance: a systematic literature review
Naylor, N. R., Atun, R., Zhu, N., Kulasabanathan, K., Silva, S., Chatterjee, A., Knight, G. M., & Robotham, J. V. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0336-y · Cited by 568
Philips, Z., Bojke, L., Sculpher, M., Claxton, K., & Golder, S. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624040-00006 · Cited by 502
The true cost of antimicrobial resistance
Smith, R., & Coast, J. (2013) · BMJ · doi:10.1136/bmj.f1493 · Cited by 488
Adjusting for Inflation and Currency Changes Within Health Economic Studies
Turner, H. C., Lauer, J. A., Tran, B. X., Teerawattananon, Y., & Jit, M. (2019) · Value in Health · doi:10.1016/j.jval.2019.03.021 · Cited by 339
Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review
Zhen, X., Lundborg, C. S., Sun, X., Hu, X., & Dong, H. (2019) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-019-0590-7 · Cited by 337
Detecting the skewness of data from the five-number summary and its application in meta-analysis
Shi, J., Luo, D., Wan, X., Liu, Y., Liu, J., Bian, Z., & Tong, T. (2023) · Statistical Methods in Medical Research · doi:10.1177/09622802231172043 · Cited by 334
Clinical and economic burden of antimicrobial resistance
Maragakis, L. L., Perencevich, E. N., & Cosgrove, S. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.751 · Cited by 329
Economic burden of antibiotic resistance: how much do we really know?
Gandra, S., Barter, D. M., & Laxminarayan, R. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12798 · Cited by 281
Nelson, R. E., Hatfield, K. M., Wolford, H., Samore, M. H., Scott, R. D., Reddy, S. C., Olubajo, B., Paul, P., Jernigan, J. A., & Baggs, J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1581 · Cited by 273
Economic Impact of Antimicrobial Resistance
McGowan, J. E. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010228 · Cited by 271
Global economic impact of antibiotic resistance: A review
Ahmad, M., & Khan, A. U. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.05.024 · Cited by 263
Thorpe, K. E., Joski, P., & Johnston, K. J. (2018) · Health Affairs · doi:10.1377/hlthaff.2017.1153 · Cited by 253
Stewardson, A. J., Allignol, A., Beyersmann, J., Graves, N., Schumacher, M., Meyer, R., Tacconelli, E., De Angelis, G., Farina, C., Pezzoli, F., et al. (2016) · Eurosurveillance · doi:10.2807/1560-7917.es.2016.21.33.30319 · Cited by 204
Kelly, S., Moher, D., & Clifford, T. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0258-9 · Cited by 169
Impact of antibiotic resistance on clinical outcomes and the cost of care
Niederman, M. S. (2001) · Critical Care Medicine · doi:10.1097/00003246-200104001-00011 · Cited by 167
Economic burden of nosocomial infections caused by vancomycin-resistant enterococci
Puchter, L., Chaberny, I. F., Schwab, F., Vonberg, R., Bange, F., & Ebadi, E. (2018) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-017-0291-z · Cited by 153
Thaden, J. T., Li, Y., Ruffin, F., Maskarinec, S. A., Hill-Rorie, J., Wanda, L., Reed, S. D., & Fowler, V. G. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01709-16 · Cited by 140
Inagaki, K., Lucar, J. A., Blackshear, C. T., & Hobbs, C. V. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz123 · Cited by 133
How to Interpret Results of Meta-AnalysisPreprint
Hak, T., van Rhee, H., & Suurmond, R. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.3241367 · Cited by 124
Zhen, X., Lundborg, C. S., Zhang, M., Sun, X., Li, Y., Hu, X., Gu, S., Gu, Y., Wei, J., & Dong, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60825-6 · Cited by 121
Jit, M., Ng, D. H. L., Luangasanatip, N., Sandmann, F., Atkins, K. E., Robotham, J. V., & Pouwels, K. B. (2020) · BMC Medicine · doi:10.1186/s12916-020-1507-2 · Cited by 120
Economic burden of antibiotic resistance in China: a national level estimate for inpatients
Zhen, X., Lundborg, C. S., Sun, X., Zhu, N., Gu, S., & Dong, H. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00872-w · Cited by 112
Klein, E. Y., Jiang, W., Mojica, N., Tseng, K. K., McNeill, R., Cosgrove, S. E., & Perl, T. M. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy399 · Cited by 91
In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella pneumoniae
Huang, W., Qiao, F., Zhang, Y., Huang, J. Y., Deng, Y., Li, J., & Zong, Z. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy642 · Cited by 85
Tabak, Y. P., Merchant, S., Ye, G., Vankeepuram, L., Gupta, V., Kurtz, S., & Puzniak, L. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.06.005 · Cited by 83
François, M., Hanslik, T., Dervaux, B., Strat, Y. L., Souty, C., Vaux, S., Maugat, S., Rondet, C., Sarazin, M., Heym, B., et al. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1620-2 · Cited by 82
Howard, D. H., Cordell, R. L., McGowan, J. E., Packard, R. M., Scott, R. D., Solomon, S. L., & the Workshop Group (2001) · Clinical Infectious Diseases · doi:10.1086/323758 · Cited by 80
Wilton, P., Smith, R., Coast, J., & Millar, M. R. (2002) · Journal of Health Services Research & Policy · doi:10.1258/1355819021927764 · Cited by 79
Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus
Antoñanzas, F., Lozano, C., & Torres, C. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0242-y · Cited by 75
Using the best available data to estimate the cost of antimicrobial resistance: a systematic review
Wozniak, T. M., Barnsbee, L., Lee, X. J., & Pacella, R. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0472-z · Cited by 74
Giraldi, G., Montesano, M., Napoli, C., Frati, P., Russa, R. L., Santurro, A., Scopetti, M., & Orsi, G. B. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190408095811 · Cited by 73
Innes, G. K., Randad, P. R., Korinek, A., Davis, M. F., Price, L. B., So, A. D., & Heaney, C. D. (2020) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043954 · Cited by 67
Zilberberg, M. D., Nathanson, B. H., Sulham, K., Fan, W., & Shorr, A. F. (2019) · CHEST Journal · doi:10.1016/j.chest.2018.12.024 · Cited by 52
Tabak, Y. P., Sung, A., Ye, G., Vankeepuram, L., Gupta, V., & McCann, E. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.11.018 · Cited by 41
The economic burden of antimicrobial resistance: Why it is more serious than current studies suggest
Smith, R., & Coast, J. (2013) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.00639028 · Cited by 38
Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients
Judd, W. R., Ratliff, P. D., Hickson, R. P., Stephens, D. M., & Kennedy, C. A. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.04.218 · Cited by 34
Burden of Antibiotic Resistant Gram Negative Bacterial Infections: Evidence and Limits
Sganga, G. (2014) · Journal of Medical Microbiology & Diagnosis · doi:10.4172/2161-0703.1000132 · Cited by 31
Jia, H., Li, W., Hou, T., Ma, H., Yang, Y., Wu, A., Liu, Y., Wen, J., Yang, H., Luo, X., et al. (2019) · BioMed Research International · doi:10.1155/2019/7634528 · Cited by 30
Iskandar, K., Roques, C. G., Hallit, S. R., Husni, R., Dirani, N., Rizk, R., Abdo, R., Yared, Y., Matta, M., Mostafa, I., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06084-w · Cited by 26
Uematsu, H., Yamashita, K., Kunisawa, S., Fushimi, K., & Imanaka, Y. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.05.008 · Cited by 19
Effect of methicillin-resistant Staphylococcus aureus in Japan
Uematsu, H., Yamashita, K., Mizuno, S., Kunisawa, S., Shibayama, K., & Imanaka, Y. (2018) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.04.214 · Cited by 17
Naylor, N. R., Silva, S., Kulasabanathan, K., et al. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0364-8 · Cited by 16
Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections
Tabak, Y. P., Sung, A., Ye, G., Vankeepuram, L., Gupta, V., & McCann, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229393 · Cited by 12
Cited by
An Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
Sono, T. M., Yeika, E., Cook, A., Kalungia, A., Opanga, S. A., Acolatse, J. E. E., Sefah, I. A., Jelić, A. G., Campbell, S., Lorenzetti, G., et al. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2259106 · Cited by 95
How Medically Important Antimicrobials Bind to the 30S Ribosomal Subunit in a Bacterial Pathogen
(2026) · doi:10.1021/acs.biochem.6c00008 · Cited by 1
Metadata
- Authors
- Poudel, A. N., Zhu, S., Cooper, N., Little, P., Tarrant, C., Hickman, M., & Yao, G.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-05-08
- Volume
- 18
- Issue
- 5
- Pages
- e0285170
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W4375956009
- Cited by
- 264
- References
- 56
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.